Targeting energy metabolism in brain cancer: review and hypothesis

Thomas N. Seyfried, Purna Mukherjee

Nutrition & Metabolism · 2005 · 223 citations · 87 references

DOIFull text

Open access

Concepts

TL;DR

Malignant brain tumors are a major health problem driven by dysregulated glycolysis, yet normal brain cells can switch to ketone bodies when glucose is low, indicating that altering the metabolic environment may offer a therapeutic strategy. The study proposes a novel brain cancer treatment that integrates metabolic control analysis with the normal cells’ ability to survive extreme physiological shifts. The approach induces a glucose‑to‑ketone transition that attacks tumors with anti‑inflammatory, anti‑angiogenic, and pro‑apoptotic effects, relying on normal cells’ genomic flexibility and validated in mouse models and pediatric astrocytoma patients on dietary restriction and a ketogenic diet. Recent orthotopic mouse brain tumor models and pediatric astrocytoma patients treated with dietary restriction and a ketogenic diet demonstrate the efficacy of this metabolic strategy.

Abstract

Abstract Malignant brain tumors are a significant health problem in children and adults and are often unmanageable. As a metabolic disorder involving the dysregulation of glycolysis and respiration, malignant brain cancer is potentially manageable through changes in metabolic environment. A radically different approach to brain cancer management is proposed that combines metabolic control analysis with the evolutionarily conserved capacity of normal cells to survive extreme shifts in physiological environment. In contrast to malignant brain tumors that are largely dependent on glycolysis for energy, normal neurons and glia readily transition to ketone bodies (β-hydroxybutyrate) for energy in vivo when glucose levels are reduced. The bioenergetic transition from glucose to ketone bodies metabolically targets brain tumors through integrated anti-inflammatory, anti-angiogenic, and pro-apoptotic mechanisms. The approach focuses more on the genomic flexibility of normal cells than on the genomic defects of tumor cells and is supported from recent studies in orthotopic mouse brain tumor models and in human pediatric astrocytoma treated with dietary energy restriction and the ketogenic diet.

References

87